研发生产孟鲁司特钠盐 马尼地平盐酸盐CAS: 151767-02-1原料药研发供应中间体现货直销

中文名孟鲁司特钠英文名Montelukast Sodium别名孟鲁斯特纳孟鲁司特纳孟卤司特钠孟鲁司特钠孟鲁斯特钠孟鲁司特钠盐马尼地平盐酸盐孟鲁司特钠.孟钠孟鲁司特钠水合物孟鲁斯特-D6钠英文别名mk-476singulairMonTELUKAST NAMK-476, SingulairMontelukast sodiumMonTELUKAST SODIUMMontelukast SodiumMontelukast, Sodium Saltsodium(R,E)-2-(1-(1-(3-(-(7-chloroqulnolln-2-yl)-3-(2-(2 hydroxypropan-2-yl)phenyl)propylthio)cyclopropyl)acetate1-[1-[[[(1R)-1-[3-[(1E)-2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneaceticsodium (1-{[(1-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl)sulfanyl]methyl}cyclopropyl)acetate2-[1-[[1-[3-[2-[(7-chloro-2-quinolyl)]vinyl]phenyl]-3-[2-(1-hydroxy-1-methyl-ethyl)phenyl]-propyl]sulfanylmethyl]cyclopropyl]acetic acid sodium saltsodium {1-[({(1R)-1-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl}sulfanyl)methyl]cyclopropyl}acetateMethyl-[E]-(+)-1-[[[(1R)-1-[3-[(1E)-2-(7-Chloro-2-quinolinyl)-ethenyl]phenyl]-3-[2-(1-hydroxyl-1-methylethyl)phenyl]propyl]mercapto]methyl]cyclopropane acetic acid sodiumCAS151767-02-1EINECS604-813-7化学式C35H35ClNNaO3S分子量608.17InChIInChI=1/C35H36ClNO3S.Na/c1-34(2,40)30-9-4-3-7-25(30)13-17-32(41-23-35(18-19-35)22-33(38)39)27-8-5-6-24(20-27)10-15-29-16-12-26-11-14-28(36)21-31(26)37-29;/h3-12,14-16,20-21,32,40H,13,17-19,22-23H2,1-2H3,(H,38,39);/q;+1/p-1/b15-10+InChIKeyLBFBRXGCXUHRJY-HKHDRNBDSA-M熔点115 °C(dec.)沸点750.5°C at 760mmHg比旋光度[α]/D +90 to +106° in methanol (c=1)溶解度DMSO: ≥8mg/mL at 60°C存储条件2-8°C稳定性Stable for 1 year from date of purchase as supplied. Solutions in DMSO, distilled water, or ethanol may be stored at -20°C for up to 1 month.外观powder颜色white to tanMerck14,6258MDL号MFCD00931431体外研究Montelukast是一种白三烯受体拮抗剂（LTRA），用于哮喘的持续治疗以及缓解季节性过敏症状。Montelukast通过与肺部和支气管中半胱氨酰白三烯受体CysLT1结合而阻断白三烯D4的作用，防止气道水肿，平滑肌收缩，以及分泌液粘稠。这减少了由白三烯引起的支气管收缩，并且使炎症较少发生。体内研究Montelukast (6 mg/kg, 每天一次，服用20天)显著抑制OVA激发的小鼠体内BAL液和肺组织中增多的嗜酸细胞，并且增加BAL液中IL-5水平。 OVA激发会增加CysLT1S受体但会减少CysLT2受体的mRNA表达。OVA激发后，Montelukast抑制增加的CysLT1但不降低CysLT2表达。